Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib in Treating Patients With Metastatic Kidney Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Velcade and Thalidomide in Patients With Myelodysplasia
- Status
- TERMINATED
- Phase
- PHASE1
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib in Treating Patients With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
- Status
- COMPLETED
- Phase
- PHASE4
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2